Drug name - Genvoya
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(3 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(4 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(4 years from now) | |
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| CN101796040A | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2013
(9 years ago) | |
| CN100402539C | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN1443189A | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN1706855A | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN1291994C | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN100375742C | GILEAD SCIENCES INC | 4-Oxo-Quinoline Compound And Use Thereof |
Jan, 2023
(3 months from now) | |
| CN1692101A | GILEAD SCIENCES INC | 4-Oxo-Quinoline Compounds And Their Use As Hiv Integrase Inhibitors |
Jan, 2023
(3 months from now) | |
| CN1956961B | GILEAD SCIENCES INC | 4 Compound Of Stable Crystal |
May, 2025
(2 years from now) | |
| CN1956961A | GILEAD SCIENCES INC | Stable Crystal Form Of 4-Oxoquinoline Compound |
May, 2025
(2 years from now) | |
| CN101679325A | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| CN103435570A | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| CN101490023B | GILEAD SCIENCES INC | Chinese Medicine Dynamics Characteristic Regulator Therapeutic Agent |
Jul, 2027
(4 years from now) | |
| CN103275033A | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| CN103435570B | GILEAD SCIENCES INC | Pharmacokinetics Character Regulator Of Therapeutic Agent |
Jul, 2027
(4 years from now) | |
| CN103275033B | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| CN101679325B | GILEAD SCIENCES INC | Chinese Medicine Dynamics Characteristic Regulator Therapeutic Agent |
Jul, 2027
(4 years from now) | |
| CN101490023A | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| IN208435B | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| IN200600529P3 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues |
Jul, 2021
(1 year, 2 months ago) | |
| IN241597B | GILEAD SCIENCES INC | Methoxy Phosphonate Nucleotide Prodrug |
Jul, 2021
(1 year, 2 months ago) | |
| IN200300009P3 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| IN200401316P4 | GILEAD SCIENCES INC | 4-Oxoquinoline Compound And Use Thereof As Pharmaceutical Agent |
Nov, 2023
(1 year, 1 month from now) | |
| IN245833B | GILEAD SCIENCES INC | 4-Oxoquinoline Compound As Hiv Integrase Inhibitor |
Nov, 2023
(1 year, 1 month from now) | |
| IN200810487P1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| IN332719B | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2682397B1 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP2682397A1 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP1301519A2 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP1301519B1 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP1636190B1 | GILEAD SCIENCES INC | Stable Crystal Of 4-Oxoquinoline Compound |
May, 2025
(2 years from now) | |
| EP1636190A1 | GILEAD SCIENCES INC | Stable Crystal Of 4-Oxoquinoline Compound |
May, 2025
(2 years from now) | |
| EP2487165A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP3112355B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP2487165B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP3112355A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP2049506A2 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP2049506B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP2049506B9 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2027
(4 years from now) | |
| EP2118082B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487161B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487161A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2118082A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP3150586B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487162B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487166A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487162A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487166B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP3150586A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Feb, 2028
(5 years from now) | |
| EP2487163A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Mar, 2028
(5 years from now) | |
| EP2487163B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Mar, 2028
(5 years from now) | |
| EP1564210B9 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP1564210B1 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP1564210A4 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP1564210A1 | GILEAD SCIENCES INC | 4-Oxoquinoline Compounds And Utilization Thereof As Hiv Integrase Inhibitors |
May, 2028
(5 years from now) | |
| EP2170851B1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2028
(5 years from now) | |
| EP2170851A1 | GILEAD SCIENCES INC | Modulators Of Pharmacokinetic Properties Of Therapeutics |
Jul, 2028
(5 years from now) | |
| EP2744810B1 | GILEAD SCIENCES INC | Tenofovir Alafenamide Hemifumarate |
Aug, 2032
(9 years from now) | |
| EP2744810A1 | GILEAD SCIENCES INC | Tenofovir Alafenamide Hemifumarate |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791
(Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(3 years from now) | |
|
US7176220
(Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(4 years from now) | |
|
US7635704
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
|
US8981103
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
|
US8148374
(Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(7 years from now) | |
|
US9891239
(Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(7 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(7 years from now) | |
|
US8633219
(Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(8 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(10 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US10039718
(Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(10 years from now) | |
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 150MG;150MG;200MG;EQ 10MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.